Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03334409 | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney… | Phase 2 | terminated | Nov 7, 2017 | Academic and Community Cancer Research United | Due to loss of funding from the private foundation source | Funding |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | Phase 2 | terminated | Jan 9, 2020 | NanOlogy, LLC | Lack of enrollment | Enrollment / accrual |
| NCT04960956 | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma | — | terminated | Jul 14, 2021 | Indiana University | Could not identify a replacement Principal Investigator. | Investigator |
| NCT03138538 | M8891 First in Human in Solid Tumors(M8891) | Phase 1 | terminated | May 3, 2017 | EMD Serono Research & Development Institute, Inc. | As part of a portfolio-level management of the company's oncology pipeline, it was decided to stop… | Sponsor / business decision |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | Phase 2 | terminated | Jun 1, 2015 | TC Biopharm | not stated | Not stated |
| NCT03549650 | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | Phase 2 | terminated | Jun 8, 2018 | Sir Mortimer B. Davis - Jewish General Hospital | Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to… | Other (stated, no rule matched) |
| NCT01954173 | Adjuvant Radiation for High Risk Bladder Cancer | N/A | terminated | Oct 1, 2013 | Emory University | Slow accrual | Enrollment / accrual |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian… | Phase 3 | terminated | Oct 1, 2018 | AGO Research GmbH | Insufficient Recruitment | Enrollment / accrual |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Calithera Biosciences, Inc | Slow Enrollment | Enrollment / accrual |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | Phase 2 | withdrawn | Jan 30, 2017 | Guru Sonpavde | Principal investigator left lead institution and efforts to open the protocol at another… | Investigator |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT01093066 | Prospective Multicentric Evaluation of a Bladder Preservation Strategy(ReChiVe) | Phase 2 | terminated | Mar 25, 2010 | Centre Hospitalier Universitaire de Saint Etienne | Difficulties in the inclusion and follow-up of patients | Other (stated, no rule matched) |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT03287050 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial… | Phase 2 | terminated | Sep 19, 2017 | University of Michigan Rogel Cancer Center | due to changing therapeutic landscape in metastatic bladder cancer and lack of… | Other (stated, no rule matched) |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | Phase 2 | terminated | Nov 23, 2009 | Morphotek | Study was terminated by sponsor due to futile results in NCT00849667 study. | Other (stated, no rule matched) |
| NCT03945786 | Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma | — | suspended | May 10, 2019 | Xuanwu Hospital, Beijing | Recuriting inclusion and exclusion criteria will be changed as COVID-19. | COVID-19 / pandemic |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or… | Phase 1 | terminated | May 11, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous… | Phase 2 | terminated | Oct 19, 2018 | BeiGene | Sponsor's decision to revisit the development approach for prostate cancer. | Sponsor / business decision |
| NCT03408652 | Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in…(MOSCAR) | Phase 3 | terminated | Jan 24, 2018 | Centre Leon Berard | lack of recruitment | Enrollment / accrual |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced… | Phase 1 / Phase 2 | terminated | Aug 9, 2019 | Pfizer | Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not… | Other (stated, no rule matched) |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic… | Phase 1 / Phase 2 | terminated | Oct 1, 2015 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial… | Phase 1 | withdrawn | Jul 31, 2018 | Washington University School of Medicine | Trial may move forward as an NCI-sponsored trial and not an investigator initiated trial. | Investigator |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic… | Phase 2 | terminated | Apr 14, 2017 | Weill Medical College of Cornell University | Lack of accrual | Enrollment / accrual |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And…(AtezoVax) | Phase 2 | withdrawn | Jul 15, 2019 | University of Utah | funding source withdrawn | Funding |
| NCT02885649 | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | Early Phase 1 | terminated | Aug 31, 2016 | Rutgers, The State University of New Jersey | Funding unavailable | Funding |
| NCT02959554 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or…(NIVOSWITCH) | Phase 2 | terminated | Nov 9, 2016 | AIO-Studien-gGmbH | not stated | Not stated |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian… | Phase 1 | terminated | Aug 1, 2018 | MaxCyte, Inc. | Sponsor shift in focus | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | Phase 2 | terminated | Aug 26, 2019 | Johannes Gutenberg University Mainz | Recruitment problems | Enrollment / accrual |
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to… | — | withdrawn | Dec 23, 2020 | TScan Therapeutics, Inc. | Lack of patient samples | Other (stated, no rule matched) |
| NCT01649180 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant…(PrE0801) | Phase 2 | terminated | Jul 25, 2012 | PrECOG, LLC. | Closed due to prolonged enrollment timelines | Enrollment / accrual |
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | Phase 2 | terminated | Dec 7, 2016 | Seattle Institute for Biomedical and Clinical Research | Competing studies | Other (stated, no rule matched) |
| NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | Phase 1 | terminated | Feb 4, 2019 | George Washington University | Sponsor discontinued the drug | Other (stated, no rule matched) |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for… | Phase 2 | terminated | Oct 8, 2020 | Latin American Cooperative Oncology Group | Not approved | Other (stated, no rule matched) |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants… | Phase 2 | terminated | Jun 22, 2010 | Agenus Inc. | Sponsor's business decision | Sponsor / business decision |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial… | Phase 2 | terminated | Feb 29, 2016 | M.D. Anderson Cancer Center | The trial was closed due to the changing efficacy of treatments for metastatic urothelial cancer. | Efficacy / futility |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma,… | Phase 1 / Phase 2 | terminated | Oct 21, 2015 | Dana-Farber Cancer Institute | The study closed primarily due to weak accrual, as well as study design limitations. | Enrollment / accrual |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | Phase 2 | terminated | Jan 24, 2017 | NanOlogy, LLC | Business reasons | Sponsor / business decision |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological… | N/A | withdrawn | Apr 4, 2019 | Rutgers, The State University of New Jersey | The study was never initiated, no patients were enrolled. It has been closed with the IRB. | Enrollment / accrual |
| NCT01253668 | Brivanib Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Dec 3, 2010 | Abramson Cancer Center at Penn Medicine | In November 2012, this study was permanently closed to new accrual at the request of the drug… | Drug supply |
| NCT02853097 | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | — | terminated | Aug 2, 2016 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT03189186 | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by… | Phase 1 | withdrawn | Jun 16, 2017 | University of California, Irvine | This study was closed due to extremely low accrual, as well as a change in care when using the… | Enrollment / accrual |
| NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy(RESIST-PC) | Phase 2 | terminated | Feb 3, 2017 | Endocyte | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | Apr 12, 2011 | Steinar Aamdal | The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol with… | Other (stated, no rule matched) |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | Phase 1 / Phase 2 | terminated | May 11, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03261336 | Oral Calcitriol With Ketoconazole in CRPC | Phase 2 | terminated | Aug 25, 2017 | Donald Trump, MD | can not meet enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 12, 2022source: clinicaltrials